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Abstract
Background: Cerebral palsy (CP) is an heterogeneous group of neurological disorders of
movement and/or posture, with an estimated incidence of 1 in 1000 live births. Non-progressive
forms of symmetrical, spastic CP have been identified, which show a Mendelian autosomal recessive
pattern of inheritance. We recently described the mapping of a recessive spastic CP locus to a 5
cM chromosomal region located at 2q24-31.1, in rare consanguineous families.
Methods: Here we present data that refine this locus to a 0.5 cM region, flanked by the
microsatellite markers D2S2345 and D2S326. The minimal region contains the candidate gene
GAD1, which encodes a glutamate decarboxylase isoform (GAD67), involved in conversion of the
amino acid and excitatory neurotransmitter glutamate to the inhibitory neurotransmitter γ-
aminobutyric acid (GABA).
Results: A novel amino acid mis-sense mutation in GAD67 was detected, which segregated with
CP in affected individuals.
Conclusions: This result is interesting because auto-antibodies to GAD67 and the more widely
studied GAD65 homologue encoded by the GAD2 gene, are described in patients with Stiff-Person
Syndrome (SPS), epilepsy, cerebellar ataxia and Batten disease. Further investigation seems merited
of the possibility that variation in the GAD1 sequence, potentially affecting glutamate/GABA ratios,
may underlie this form of spastic CP, given the presence of anti-GAD antibodies in SPS and the
recognised excitotoxicity of glutamate in various contexts.
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Cerebral palsy (CP) is a term used to define a group of dis-
orders [1] characterized by a non-progressive abnormality
of posture and movement, resulting from defects in the
developing nervous system [2]. Approximately 1 in 250 to
1000 live births presents with CP, making it one the com-
monest congenital disabilities [3]. Many different aetio-
logical factors have been implicated. Among preterm
infants, the incidence of CP generally increases with
decreasing gestational age and the origin in most cases
may be traced to post/peri-partum periventricular leu-
komalacia and intraventricular/periventricular haemor-
rhage [4]. Conversely in term infants perinatal causes can
only confidently be attributed where there is documented
perinatal hypoxia/acidosis and clinical encephalopathy in
the early neonatal period [5]. Prenatal risk factors in the
aetiology of CP include low birth-weight, intrauterine
infection and exposure to teratogens during pregnancy
[6,7]. The cause in a large proportion of cases remains
obscure.
Depending on the overall clinical picture, CP can be sub-
classified into a number of phenotypic groups [8,9]. Dys-
kinetic CP accounts for ~20% of all cases, which may be
further divided into choreoathetotic (5%) and dystonic
(15%) forms. Ataxic CP (~10% of all cases) can also be
sub-divided into two forms, simple (congenital) ataxia
(5%) and ataxic diplegia (5%). Spastic CP is the most
prevalent sub-type (~70%) and was the phenotype of the
probands in this study [10]. It is characterised by muscular
hypertonicity and pronounced rigidity of the affected
limbs. Spastic CP can be sub-classified according to the
topography of the affected limbs as hemiplegic (20%),
monoplegic (<1%), diplegic (40%), or quadriplegic
(10%) [11].
Kuban and Leviton [3] suggested that CP could be genetic
in origin, as well as the result of environmental insult at
any point during CNS development. Most estimates place
the proportion of CP cases with a genetic aetiology at
between one and two percent of the total [12]. Among
infants and children with spasticity, symmetry of neuro-
logical signs has been identified as a strong indicator of a
probable genetic aetiology [13,14]. The proportion of
cases demonstrating Mendelian inheritance varies among
the different sub-types of CP [2,13,7]. X-linked, auto-
somal dominant and recessive inheritance patterns have
been described for non-progressive CP. An ataxic diplegic
autosomal recessive trait (OMIM:605388) [15] has been
mapped to chromosome 9p12-q12. Progressive spastic
paraplegia (SPG) has a similar pathology to CP. SPG dis-
plays autosomal dominant (SPG3A at 14q11-q21 encod-
ing the atlastin GTPase; SPG4 at 2p21-22 encoding
spastin, an AAA family ATPase/chaperonin; SPG6 at
15q11.1; SPG8 at 8q23-q24; SPG9 at 10q23-q24; SPG10
at 12q13; SPG12 at 19q13; and SPG13 at 2q24 encoding
the HSP60 mitochondrial chaperonin), recessive (SPG5A
at 8cen; SPG7 at 16q24.3 encoding paraplegin, an AAA
family ATPase/inner mitochondrial membrane chaper-
onin; SPG11 at 15q13-q15; SPG14 at 3q27-q28; SPG15 at
14q22-q24; and SPG17 at 11q12-q14), or X-linked inher-
itance patterns (SPG1 at Xq28 encoding the L1CAM adhe-
sion molecule; SPG2 at Xq22 encoding proteolipid
protein-1; and SPG16 at Xq11.2).
A non-progressive, autosomal recessive, symmetrical spas-
tic CP locus has been mapped to a 5 cM region between
D2S124 and D2S333, at 2q24-31.1 (LOD score of 5.75)
in consanguineous families originating from the Mirpur
region of Pakistan (OMIM:603513) [10]. Affected indi-
viduals had no identifiable perinatal cause of CP, or
underlying diagnosis and presented with developmental
delay, mental retardation and sometimes epilepsy as part
of the phenotype. We initially performed detailed physi-
cal mapping of the 5 cM region, so as to accurately define
the marker order and to refine the linkage interval. The
positions of a large number of genes and ESTs were
defined accordingly, allowing the rapid identification of
candidate disease genes. The minimum region of
homozygosity was reduced to 0.5 cM by typing large num-
bers of microsatellite markers in the families. Subse-
quently, portions of this region have been sequenced in
the human genome project. Within the region we have
concentrated on the positional candidate GAD1, which
codes for the 67 kDa isoform of L-glutamate decarboxy-
lase (GAD EC:4.1.1.15).
GAD requires the cofactor pyridoxal 5'-phosphate (PLP)
and catalyses the production of Gamma-aminobutyric
acid (GABA) from glutamate [16]. Two separate, inde-
pendently-regulated genes, GAD1 and GAD2 (at chromo-
some 10p11, encoding a 65 kDa GAD isoform), have
presumably arisen by duplication and been conserved
during evolution, as indicated by their sequence hom-
ology [17] and the retention of common intron-exon
boundary splice sites [18]. Their N-termini demonstrate
~23% homology, but their C-termini, which contain the
catalytic site, have ~73% amino acid sequence identity
between the isoforms [19]. GABA and glutamate are the
most abundant amino acid neurotransmitters in the
brain. GABA, an inhibitory neurotransmitter, and excita-
tory glutamate, both play important roles in synaptic plas-
ticity and neuroendocrine function [20]. Both isoforms of
GAD are also involved in intermediary metabolism, par-
ticipating in the GABA shunt, which bypasses two steps of
the TCA cycle [21]. GAD activity of both isoforms, is ubiq-
uitous, but highest in the brain and pancreatic islets of
Langerhans. We therefore performed detailed mutational
screening of GAD1 in familial spastic CP probands and
unaffected family members.Page 2 of 14
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Features and pedigrees of ascertained families
Family A (4718/4719)
The oldest affected male diagnosed with non-progressive,
spastic CP, demonstrated global developmental delay,
with no associated neurological abnormalities and mod-
erate mental retardation. His affected younger sister was
also diagnosed with spastic CP, global developmental
delay and moderate mental retardation.
Family B (4578/4579/4581/4679)
The oldest non-progressive, spastic CP female has severe
mental retardation, and is confined to a wheelchair. The
next oldest spastic CP male has severe mental retardation,
mild hypertonia and ataxia of the upper limbs. The next
oldest spastic CP male is a dizygotic twin born by Caesar-
ean section. This patient on presentation demonstrated
developmental delay, mild hypertonia and ataxia of the
upper limbs. The youngest affected female is not able to
walk or stand unaided and has severe developmental
delay. Details of the clinical picture in these pedigrees
have been described previously [10,14].
Physical mapping of candidate region
ICI and CEPH YAC libraries were screened by PCR ampli-
fication of STSs that were mapped between D2S2157 and
D2S385. The positive clones (CEPH human mega YAC
clones: 761-G10, 797-G4, 842-G1, 842-G3, 910-G12,
945-C12; ICI human YAC clones: 13I-E10, 13I-G11, 14I-
G12, 16F-H2, 1E-F6, 21E-G5, 30A-D10, 30H-D2, 33D-
C4, 35B-D2, 18B-E3, 31H-A4, 40D-E8, 8D-E12, 9H-F10)
were obtained from the UK HGMP Resource Centre http:/
/www.hgmp.mrc.ac.uk/. Clones were grown up in
casamino acid selective broth overnight and harvested by
centrifugation. The pellet was then washed twice in 0.5 ml
100 mM Tris-HCl, pH7.5, 0.5 M EDTA buffer. After a sec-
ond round of centrifugation the pellet was resuspended in
molten 1% LMP agarose in 5 mM Tris-HCl, pH7.5, 0.05
M EDTA, 10 mM NaCl with 100 µg of Zymolase. The aga-
rose was cooled and the resultant plugs were incubated
overnight at 37°C in 50 ml of 0.5 M EDTA, 10 mM Tris-
HCl, pH7.5, 10 mM NaCl. The buffer was replaced with
fresh solution to which 100 µl of 40% Sarkosyl NL30 and
50 µl Proteinase K (1 mg/ml) was added and the plugs
were incubated overnight at 50°C.
The YAC chromosomal DNA was purified and separated
for sizing by CHEF electrophoresis. The switching angle
was 120°, using a CHEF™ electrophoresis tank (Bio Rad),
run for 16 hours at 6 V/cm, 10°C with an initial pulse
time of 30 sec to a final pulse time of 90 sec. DNA was
stained with (20 mg/ml) ethidium bromide solution
(BDH) for 2 hours and visualized under ultra-violet illu-
mination. Southern blotting and membrane hybridisa-
tion of CHEF gels were performed on Hybond-N™
membranes (Amersham). DNA was immobilised by heat-
ing the membrane to 80°C in vacuum for 1 hour in a gel
dryer (Bio-Rad). Radio-labelled YAC vector-specific
probes were generated using the Megaprime random
primer kit (Amersham) as described in the manufacturer's
instructions, using PCR products as a template. Sizes were
estimated based on comparisons with the known sizes of
the native yeast chromosomes.
Genetic mapping
The microsatellite markers: Cen-D2157, D2S124,
D2S2330, CHLC.GATA71B02 (D2S1776), D2S2345,
CHLC.GATA71D01, D2S294, AFMA109YC1, D2S376,
D2S2284, D2S2177, D2S2194, D2S333, D2S2302,
D2S2381, D2S326, AFMA304WB1, D2S138, D2S148,
D2S300-Tel, were amplified using fluorescently labelled
primers (Lifetech) previously designed by the Whitehead
Institute or on the GDB database http://
www.ncbi.nlm.nih.gov, http://www.genome.wi.mit.edu/,
http://www.marshfield.org/genetics/. These primers were
used to amplify microsatellite marker alleles from individ-
uals by PCR. Individual alleles were identified by denatur-
ing polyacrylamide gel electrophoresis on an ABI Prism
377 sequencer and analysed using Genescan™ and Geno-
typer™ (version 1.1.1) software (Applied Biosystems).
Single-strand conformational polymorphism analysis
GAD1 exon sequences were amplified by PCR using the
primers described in Table 1. SSCP was performed on
GeneGel Excel (Amersham), using a 12.5/24 gel (14°C,
600 V, 25 mA, 15 W for 80 min) and the DNA was visual-
ised by silver staining as per the manufacturer's
instructions.
Sequencing of GAD1 exon sequences
Primers used to amplify the exons of GAD1 were designed
from the sequence of BAC RP11-570c16 and obtained
from Lifetech (Table 1). PCR products were purified from
agarose gels using QIAquick gel extraction kits (Quiagen),
sequenced using ABI PRISM Big Dye Terminator Cycle
Sequencing Ready Reaction Kits (Applied Biosystems)
and then analysed using an ABI Prism 377 automated
sequencer.
Results
Physical map of the spastic CP locus
An integrated YAC (ICI and CEPH mega YAC libraries)
and RP-9 PAC (HGMP Resource Centre) contig for the
interval D2S2157 to D2S385 was constructed (Figure 1).
This map provided physical continuity connecting 25 loci
from centromere to telomere spanning the entire 2q24.3-
31.1 cytogenetic band region. These data were combined
with BAC contigs, constructed at Washington University
http://genome.wustl.edu/gsc, in an attempt to form an
ordered BAC/YAC contig across the minimum region ofPage 3 of 14
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Primer Forward Reverse
Exon 1 dGCCCCATTTATTTCCCAGCC dGCACAGCTCTCGCTTCTCTT
Exon 2 dGAAAACCATTGTCCTCCACC dGCCTGTCGGCTCACAGATT
Exon 3 dACCAGCTTCTTGTGCCATAG dATCTACTGGCTAGCATGGGG
Exon 4 dATTCCATGTCTGAGCAGCCT dACTGTTACTGCCCAAGCTTG
Exon 5 dGCCGTTTGCCTTCAAGATAG dAGAACCACTGGGACTGAACT
Exon E dACCAGTATCTCCTCGCCATG dTTGGGAGGCCCCTGGAAATT
Exon 6 dACCCAACTACAAATACTAAACC dAATAGGAAGTCAGGGTATCC
Exon 7 dGAGACACCAGCTCAGCGTTC dCTGCAACAAACAGAGGCTCG
Exon 8 dGTCGGGGATGCTTTCTCCATG dCTCAGTACATTGTGCCAAGC
Exon 9 dCAAGCTGCTAATGGTCTGTT dGTCTCATATTATCAAGGACTG
Exon 10 dCACAATTCTTCTTCCTGTGA dTGGGGAGGAGCTTGAGGCAA
Exon 11 dACAATCAGTGTGGGCTGAAC dGAAGCAAACTTAGACCGAAA
Exon 12 dCTTGAGTTGGAATGGGTGTT dACTGCAAAGAGACCCCACGT
Exon 13 dTCCTTCCAAGCAGCCTAGTT dGTGATATATCTTTGCCCCTC
Exon 14 dGACAGCATAGCCTTCCCAAA dCATGTTGCCAGAAGCTTCAG
Exon 15 dGGTTTGGGAACAGCTTTCTC dTTCCCCCACTAGAAAGGCAC
Exon 16 dGTTAAAAAGAGAGGGTGTTC dCCCTCAATGAAATGGCCTGT
An integrated physical YAC contig spanning the human chromosome 2 spastic CP locusFigur  1
An integrated physical YAC contig spanning the human chromosome 2 spastic CP locus. This was constructed against a 
framework of microsatellite and STS markers, to incorporate the region of linkage identified by genotyping data. The positions 
of microsatellite and STS markers are represented numerically left to right from centromere to telomere. These loci 1–25 
were mapped arbitrarily equi-distant onto the contig, in the following order: Cen-(1) D2S2157; (2) D2S382; (3) WI-18792; (4) 
D2S124; (5) D2S111; (6) D2S2384; (7) D2S2330; (8) D2S399; (9) D2S2345; (10) D2S294; (11) D2S2188; (12) D2S2284; (13) 
D2S2177; (14) D2S335; (15) D2S326; (16) D2S2381; (17) D2S2302; (18) D2S2307; (19) D2S2257; (20) D2S2314; (21) D2S138; 
(22) D2S148; (23) D2S2173; (24) D2S300; (25) D2S385-Tel.Page 4 of 14
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2) enabling the physical length of the region to be esti-
mated. The partial contig map included 3 identified CEPH
mega-YAC contigs (contig 1: 945-C12; 912-B6; 744-G6;
797-G4; 761-G10; contig 2: 752-G9; 757-E1; 807-H5;
842-G1; 842-G3 and contig 3: 964-H5; 935-E10; 855-H2;
785-G8; 963-D11; 751-H3). The size of the region incor-
porating the three contigs was estimated to be at least
2870 kb. The sizes of the ICI YACs were estimated to
encompass a minimum locus of 2940 kb. Microsatellite
markers, ESTs and known genes, mapped to this region by
NCBI, were then located on the physical contig by PCR
and BLAST sequence homology searches of the Washing-
ton University BAC contigs. The expression profiles of
unidentified EST clusters were determined and used to
form EST "bins". These contained groups of ESTs, which
mapped to adjacent locations and showed common
expression profiles, suggesting that they might represent
different exons of the same gene. This placement of
known genes and ESTs onto the physical map provided an
annotation of the gene content of the region, at the time
was constructed before any such facility was available
from the HGP, as the focus for candidate disease gene
selection.
Genetic mapping data
From the PAC/YAC contig, 20 polymorphic microsatellite
markers were identified that span the chromosome 2q24-
31.1 CP critical region. These were then used, with
informed consent and local research ethics committee
approval, in the detailed mapping of previously linked
families [10] (Figure 2). These data did not support the
presence of a founder mutation for autosomal recessive
spastic CP, in that families did not share a common hap-
lotype across the minimal homozygous region between
D2S2345 and D2S326.
Sequence analysis of GAD1
GAD1 was sequenced in affected and unaffected individu-
als in both families ascertained. In order to differentiate
possible disease-causing mutations from polymorphisms,
100 control individuals were screened by SSCP to detect
any GAD1 sequence variations in the normal population.
SSCP variants were then sequenced to identify the under-
lying nucleotide substitutions. An homozygous G(36)C
(Figure 3A,3B) nucleotide change was observed in 4
affected patients, which generated a Ser(12)Cys amino
acid substitution. No obligate carriers were identified for
this mutation. This variant has not been previously
described and was not present in 200 normal chromo-
somes. A number of other sequence changes were
detected, but none of these resulted in amino acid
changes. These variants and all those recorded previously
in the literature are presented in Table 4 and Figure 4. For
those rare variants in the databases, which result in amino
acid changes, no homozygous or compound hetero-
zygous individuals have yet been described.
Table 2: Approximate sizes of YAC clones spanning the 2q24-31.1 autosomal recessive spastic CP disease gene locus, used to estimate 
the minimum physical size of the region (kb). The CEPH MEGA and ICI YACs were sized using CHEF PFGE compared against the 
native yeast chromosomes. This confirmed the estimated size ranges of the YAC inserts, predicted by the Whitehead Institute (WI) 
database of YAC clones.
CEPH human MEGA-YAC clones ICI human YAC clones
Clone Size (kb) Clone Size (kb)
910-G12 1630 40D-E3 290
744-G6 1120 35B-D2 260
912-B6 1190 33D-C4 120, 480
945-C12 1540 30H-D2 250
842-G3 1330 30A-D10 260
797-G4 1000 18B-E3 120
807-H5 1680, 1290 16F-H2 220
752-G9 1740 13I-G11 230
785-G8 690, 1060 13I-E10 460
842-G1 1380 8D-E12 280
757-E1 1100
812-G1 1540
863-H12 1550
935-E10 1360
785-G8 1060
751-H3 1780
963-D11 1670, 890Page 5 of 14
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CP is a term used as a collective definition for a group of
neurological disorders [3]. The pathophysiology in most
cases is poorly understood, but includes genetic syn-
dromes, congenital malformation, infective intra-uterine
encephalitis, cerebral haemorrhage or infarction, ischemic
damage, periventricular leukomalacia (PVL), and non-inf-
arctive telencephalic leukomalacia [11]. The contribution
of Mendelian inherited cases of CP accounts for approxi-
mately 2% of the total number [2,22]. A non-progressive
form of autosomal recessive spastic CP has been identified
[13]. McHale et al. [10] succeeded in identifying a 5 cM
region on chromosome 2q24-31.1, which segregated with
disease in consanguineous families. Linkage analysis
identified a locus between markers D2S124 and D2S333,
which produced a LOD score of 5.75, sufficient to warrant
the further investigation described herein.
To refine and confirm the genetic marker order across a
region, which was incompletely sequenced at the time, we
used YAC and PAC clones to construct a physical frame-
work and performed PCR to map ESTs and microsatellite
markers to clones within the partial contig (Figure 1).
When this contig was integrated with the BAC sequence
contigs, rearrangement of the BAC order was necessary.
With each subsequent DNA sequence update, the degree
of inconsistency was reduced and this led to revision of
microsatellite order compared with that used previously
[10]. Using the YAC sizes, the sizes of gaps in the BAC con-
tig could be estimated. Having generated a detailed map
Annotation of two pedigrees of spastic autosomal recessive CP families and corresponding linkage mapping dataFigure 2
Annotation of two pedigrees of spastic autosomal recessive CP families and corresponding linkage mapping data. The 
markers shown are those that demonstrate the minimal homozygous region between the affected individuals of both families.Page 6 of 14
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evenly spaced intervals across the locus. These markers
were used to refine the minimum region homozygous by
descent in linked families, to between the markers
D2S2345 and D2S326. The physical size of the region
between these markers is approximately 0.5 cM. There was
no suggestion of a founder haplotype common to the two
families (Figure 2).
The Goldenpath Human Genome Working Draft Assem-
bly 2001, is an annotation of the Washington BAC contig,
combining sequence data of BACs, ESTs, known genes
and hypothetical genes. We mapped ESTs and known,
uncharacterised or hypothetical genes on the basis of
sequence homology (NCBI http://
www.ncbi.nlm.nih.gov, Whitehead http://
www.genome.wi.mit.edu and Goldenpath databases),
onto our YAC/PAC contig. ESTs were then collated accord-
ing to their expression profiles to produce a "binned" EST
map, on which candidate gene selection could be based.
This reduced the number of hypothetical genes in the
region and allowed the combination of genetic, physical
mapping and expression data, into a single comprehen-
sive map.
Electropherograms of the sequence of the exon 1 SNP of GAD1 identified in the process of mutational analysisFigu e 3
Electropherograms of the sequence of the exon 1 SNP of GAD1 identified in the process of mutational analysis. (A) 
and (B) show the normal C variant in the forward and reverse directions, respectively. (C) and (D) show the alternative G var-
iant in the forward and reverse directions, respectively. This variant was only found in affected individuals of family B. No het-
erozygous individuals were identified for this nucleotide variant.
(A) (B)
(C) (D)Page 7 of 14
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GAD1, which encodes GAD67. Expression of its transcript
is ubiquitous, including the CNS. The main function of
GAD67 is to catalyze the conversion of the excitatory
amino acid and neurotransmitter glutamate to GABA, the
main inhibitory neurotransmitter in the CNS [23]. In the
Table 3: Autozygosity mapping data generated by genotyping eight members of the two autosomal recessive spastic CP families. 
Subjects 4718, 4719, 4720 and 4722 represent family A; subjects 4578, 4579, 4581 and 4679 represent family B as demonstrated in 
Figure 2. This Table is organised according to the definitive marker order determined from current databases and the physical contig 
mapping undertaken. The minimum homozygous region is highlighted. *Denotes an unaffected family member.
Marker Base 
position
4718 4719 4722* 4720* 4578 4579 4581 4679
D2S2157 AFMA119YH5 166029867 145 145 145/147 145 145/147 145/147 145/147 145/147
D2S124 AFM094ZC9 166347755 160 160 160 160 160/163 160/163 160/163 160/163
D2S2330 AFMC015YD9 166900134 156 156 156/158 156/158 160/168 160/168 160/168 160/168
CHLC.GATA71B02 167624503 240/256 240/256 240/256 240/256 240/256 240/256 240/256 240/256
D2S2345 AFM080XG9 168922932 156 156 150/156 150/156 152 152 152 152
CHLC.GATA71D01 169848018 193 193 193 193 193 193 193 193
D2S294 AFM205XF12 170579380 186 186 186 186 208 208 208 208
AFMA109YC1 171576976 256 256 254/256 256 254 254 254 254
D2S376 AFM319XG1 171576985 235 235 235 235 235 235 235 235
D2S2284 AFMB314YE1 171696071 166 166 166 166 166 166 166 166
D2S2177 AFMA155TF9 171790203 118 118 118 118 128 128 128 128
D2S2194 AFMA222XB9 171884139 141 141 141 141/143 145 145 145 145
D2S333 AFM2702E9 172592103 189 189 189/191 189/191 189 189 189 189
D2S2302 AFMB342ZD9 172758604 204 204 199/204 199/204 204 204 204 204
D2S2381 AFMA082TF5 172861090 222 222 226 222/226 224 224 224 224
D2S326 AFM266VE1 173299492 92 92 92 92 92 92 92 92
AFMA304WB1 176057526 130/132 122/132 130/132 122/132 124 124 124 124
D2S138 AFM176XD4 177947395 108 108 113 108/113 111/117 111 111 111
D2S148 AFM200WA11 178434054 184/188 184/188 184/194 184/194 188/190 186 186 186
D2S300 AFM214XC3 178826338 87/89 87/89 87/89 87/89 87/89 89 89 89
Table 4: GAD1 single nucleotide substitutions detected on mutation analysis and occurring in sequences submitted to NCBI SNP 
database and in the literature. This is not a definitive list, but includes those described at the time of the mutational analysis. 
*Nucleotide positions were not provided by Maestrini et al. [47].
Source SNP position in mRNA, 
from the translational 
start site (bp)
Gene position of 
SNP(bp)
Amino acid change
(A)Lappalainen et al. (2002) A(-478)Del Exon 0 (73) No substitution
(B)Lappalainen et al. (2002) G(-147)A Exon 0 (404) No substitution
(C)Lappalainen et al. (2002) A(-39)C Exon 1 (25) No substitution
(D)Spastic CP patients family B G(36)C Exon 1 (97) Ser(12)Cys
(E)NCBI collated resource G(48)C Exon 1 (104) Pro(17)Ala
(F)Control samples & family A NCBI collated resource T(110)C Exon 2 (29) No substitution
(G)Kure et al. (1998) T(315)C Exon 4 (14) No substitution
(H)Bu and Tobin (1994) Kure et al. (1998) A(407)G Exon 4 (105) No substitution
(I)Maestrini et al. (2002)* G/C Intron 4 No substitution
(J)NCBI collated resource C(696)T Exon 6 (56) No substitution
(K)Lappalainen et al. (2002) T/Del Intron 7 (35) No substitution
(L)In control samples Lappalainen et al. (2002) T/C Intron 8 (185) No substitution
(M)Maestrini et al. (2002)* C/T Intron 9 No substitutionPage 8 of 14
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differentiation and the control of plasticity [21]. GABA
has also been implicated in the pathogenesis of various
seizure and movement disorders [20].
Vertebrates have two separate genes coding for GAD,
which produce distinct forms of the enzyme. GAD1 and
GAD2 have diverged relatively recently in evolution, as
indicated by their degree of sequence homology and the
retention of common intron-exon boundary splice sites
[17] (Figure 5A). The variants of GAD differ in molecular
weight, cellular and sub-cellular localisation, and their
interaction with the cofactor PLP [18,20,24].
GAD2, located at 10p13-p11.2, is transcribed to produce
a 5.6 kb mRNA in islets and brain, encoding a 65 kDa pro-
tein (585 AA residues). The 67 kDa (594 AA residues)
form [17] is localised to 2q25-26 and encoded by a 3.7 kb
transcript (GAD1) [23]. There is also evidence for a 25
kDa inactive protein (GAD25) produced from an alterna-
tively spliced GAD1 transcript of 2 kb that contains an in-
frame stop codon. This GAD1 splice variant has only been
found in human islets, testis and adrenal cortex, although
the homologue is present in fetal mouse brain [25].
GAD67 and GAD65 consist of two major sequence
domains (Figure 5B). The N-termini (AA residues 1–94 in
GAD65 and 1–101 in GAD67) demonstrate ~23% hom-
ology. These N-terminal domains are thought to be
responsible for sub-cellular targeting and the formation of
GAD65–GAD67 heterodimers [26]. The C-terminal
domains (AA residues 96–585 in GAD65 and 102–594 in
GAD67) contain the catalytic site, with ~73% sequence
identity between the isoforms [19] (Figure 5).
In the CNS, GAD65 appears to be preferentially distributed
in axon terminals and the associated synaptic vesicles,
whereas GAD67 is also located in the cell bodies and more
uniformly distributed throughout the neuron [24]. This
suggests that each GAD isoform is involved in the synthe-
sis of GABA in different sub-cellular compartments [21].
This is supported by the discovery that GAD65 is the main
source of apoGAD (an inactive reservoir), which responds
to short-term changes in neuronal activity and is more
responsive to levels of PLP [18]. On the other hand,
GAD67 predominantly exists bound to the PLP cofactor
(holoGAD), providing a constitutive level of GABA pro-
duction [20]. Bond et al. [27] showed that GAD25 is
expressed in a temporally controlled manner, in the devel-
An annotation of the distribution of single nucleotide substitutions identified in the open reading frame of GAD1Figure 4
An annotation of the distribution of single nucleotide substitutions identified in the open reading frame of GAD1. The 
approximate positions with respect to intron-exon of the open reading frame structure are illustrated. These were determined 
by sequencing of the probands in this study, from published data and from the NCBI collated database of SNPs. The letters 
refer to the SNPs listed in Table 4. Upper case letters refer to SNPs in the cDNA and lower case letters indicate SNPs in the 
genomic DNA. A: G(36)C, B: G(210)A, C: G(253)C, D: T(315)C, E: A(407)G, F: C(696)T, G: C(1506)T, H: C(1575)T, i: 
T(1625)G, J: C(1654)T, k: A(1659)G, l: G(1799)A, m: C(1899)A.
cDNA
Genomic
3’ UTR
A              B   C D E    F  G   H           J   
5’ UTR
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Three illustrations of the genomic, protein and comparative sequence homologies of the different species of GAD. (A) 
The genomic structures of GAD1/GAD25/GAD2 and Drosophila Gad1. (B) Comparative protein domain structures of GAD65/
GAD25/GAD67 and Drosophila Gad1. (Numbers represent approximate amino acid residues). (C) Schematic illustrating the rel-
ative homology of the protein structures of GAD67/GAD65 and Drosophila Gad1.
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provide a mechanism of regulating GABA production in
differentiating neurons.
Asada et al. [28] undertook the selective elimination of
each GAD isoform in order to determine their respective
roles. Gad2-/- mice are slightly more susceptible to sei-
zures, consistent with an excitatory increase in the relative
ratio of glutamate/GABA. However, they showed no obvi-
ous overall change in neuronal GABA content. Therefore
GAD67 alone appears to produce sufficient GABA for effec-
tive neurotransmission [21]. Gad1-/- mice demonstrated a
decrease of ~20% in total glutamate decarboxylase activity
at birth. This was assayed by the conversion of 14C-
labelled glutamate to 14CO2 in the presence of PLP. There
was also a marked (7%) reduction in total GABA content
in cerebral cortex homogenate measured by liquid chro-
matography [28]. Unfortunately, these mice died neona-
tally of severe cleft palate, masking any potential
neurological dysfunction and also illustrating a role for
Gad67 in non-neural tissues [21]. It is of interest that mice
with mutations in the β-3 GABA receptor (GABRB3) at the
Angelman syndrome (OMIM:105830) locus, also display
cleft palate, implying a key role for GABA signalling in
normal palate development [29,30].
Pyridoxine-dependent epilepsy (PDE) is a rare autosomal
recessive disorder (OMIM:266100), characterized by gen-
eralized seizures during the first hours of life. The associ-
ated pathology may result from an alteration in the
binding of the co-factor PLP to GAD. Interestingly epi-
lepsy is commonly associated with CP and grand mal epi-
lepsy developed at age six months in the two linked
pedigrees described here [10]. GAD1 mutation was previ-
ously suspected of being the cause of PDE. Linkage of pyri-
doxine-dependent epilepsy has however been reported to
5q31.2-31.3, with GAD1 and GAD2 excluded [31].
Decreased levels of brain and CSF GABA, increased levels
of CSF and cortical glutamate, and decreased levels of PLP
in the frontal cortex, have been described in this
condition.
GAD65 and GAD67 have been identified as auto-antigens
in "Stiff Person Syndrome" (SPS, OMIM:184850), and in
cerebellar ataxia [32-34]. GABA-mediated synaptic
transmission is thought to be functionally impaired by
the production of autoantibodies to GAD65 and GAD67
[35-37]. This results in a reduction in brain levels of
GABA, prominent in the motor cortex, which can be dem-
onstrated by Magnetic Resonance Imaging (MRI) in SPS
patients. SPS is a disabling disorder characterised by mus-
cle rigidity and episodic spasms of the musculature,
thought to be due to autoimmune-mediated dysfunction
of supraspinal GABAergic inhibitory neurons [38]. Hyper-
excitability of the motor cortex in SPS has been demon-
strated by transcranial magnetic stimulation [39].
Anti-GAD65 auto-antibodies in the CSF of ataxic and SPS
patients selectively suppress GABA-mediated
transmission in cerebellar Purkinje cells, without affecting
glutamate-mediated transmission [37,40]. Low CSF levels
of GABA have been reported in patients with Kok disease
(OMIM:149400 also known as hyperexplexia/exaggerated
startle reaction/startle disease) [41]. The exact mechanism
by which autoantibodies target these intracellular GAD
antigens is not clear. However, it is interesting that SPS
may also arise in individuals with autoantibodies to
gephyrin, a cytosolic protein concentrated at the postsyn-
aptic membrane of inhibitory synapses where it is
associated with GABAA receptors [42]. This provides a fur-
ther example of chronic rigidity and spasm possibly sec-
ondary to disruption of the inhibitory synapses.
Mutations in the CLN3 gene are thought to be responsible
for the neurodegenerative disorder Batten disease
(OMIM:204200). In cln3-knockout mice autoantibodies
to GAD65 have been reported to be associated with brain
tissue and result in inhibition of GAD activity [43]. These
mice also demonstrate elevated brain glutamate levels as
compared with controls, which may have a causative role
in the astrocytic hypertrophy evident in cln3-knockout
mice and along with anti-GAD65 autoantibodies in Batten
disease patients may contribute to the associated preferen-
tial loss of GABAergic neurons.
Drugs, which potentiate the action of GABA, such as ben-
zodiazepines and baclofen, ameliorate muscle rigidity
and spasticity. These GABA agonists are thought to coun-
ter disinhibition of the velocity-dependent increase in
skeletal muscle during stretch reflexes, observed in spastic-
ity, which is the result of inadequate presynaptic inhibi-
tion of the muscle spindles [44,35,37]. γ-Vinyl-γ-
aminobutyric acid (GVG) is used to treat neurological dis-
orders including epilepsy, tardive dyskinesia and spastic-
ity. It has been reported that it is the GABA-elevating effect
of this compound that is responsible for its anti-convul-
sive properties [20].
We have identified a GAD1 sequence change G(36)C,
which segregates with autosomal recessive spastic CP in 4
affected siblings. This nucleotide substitution causes a
missense mutation, changing serine (12) to a cysteine in
the N-terminal domain. This serine residue is conserved
between all mammals (human/mouse/rabbit/pig) for
which data are available. The association of GAD67 with
membranes requires formation of heteromeric links with
GAD65, which are mediated via their N-terminal domains.
The N-terminus of GAD65 is palmitoylated and binds to
the cellular membrane. The first 27 amino acids appear toPage 11 of 14
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cysteines 30 and 45 of GAD65, and the inability of residues
1–29 of GAD67, to substitute for this region, highlights the
potential impact on cellular localisation of a nucleotide
substitution in this domain [20]. GAD65 also undergoes
phosphorylation of the first four serine residues in the N-
terminal domain. These post-translational modifications
highlight the importance of the flexibility and accessibil-
ity of this domain. N-terminal epitopes of GAD65, in the
region corresponding to the residue, which undergoes
mutation in GAD67, are particularly prominent autoanti-
gens [45].
S(12)C amino acid substitution may thus produce subtle
effects on cellular localisation, protein-protein interac-
tions and/or protein processing, with a subsequent effect
on GABA production. This is not inconsistent with the
mouse Gad1 knockout where complete loss of Gad1 enzy-
matic function (~20% reduction of total Gad activity in
the cerebral cortex) resulted in a cleft palate phenotype
and neonatal death [28,30]. There is redundancy of GABA
production as a result of the presence of two GAD pro-
teins, and the precise function of each isoform may differ
between man and mouse. It is interesting to note that the
GAD25 splice variant of GAD67, also contains the S(12)C
amino acid substitution in affected CP patients. This trun-
cated variant is identical to the first 213 amino acids of
GAD67, with the addition of an extra 11 C-terminal resi-
dues. It lacks the binding site for the cofactor PLP and is
believed to lack any GAD activity [25]. The function of
GAD25 is not known, but it may compete with GAD67 for
incorporation into protein complexes. Therefore the pres-
ence of an N-terminal mutation would affect both GAD25
and GAD67, and may disrupt a complex regulatory mech-
anism for GAD67.
Conclusions
This study illustrates the difficulty of gene cloning in rare
autosomal recessive diseases mapped in small, consan-
guineous pedigrees. Identification of an ancestral
haplotype allows refinement of the locus, but this has not
been possible in this example. Within the minimal
linkage region, any sequence change will segregate with
the disease phenotype. Detection of a nonsense mutation
leading to a protein truncation would provide compelling
support for a mutation as causative. However, in the
present example we have not seen such a mutation in the
candidate gene so far examined. We are now expressing
the variant forms of GAD67 (S12C) and GAD25 (S12C), as
recombinant proteins, to assess catalytic activity and bind-
ing properties with respect to their normal counterparts.
However, it may well prove difficult to detect subtle effects
based on sub-cellular localisation changes in the mutant
proteins, or changes in post-translational modification
patterns.
Stability of the mRNA transcripts from these variants will
be assessed by transfection studies in neuronal cells. Even-
tually, it would be of interest to attempt knock-in experi-
ments with GAD1 (G36C), into the Gad1-/- mouse to see
if this can rescue the cleft palate phenotype and reveal a
CP-like picture. These experiments will be reported else-
where. However, the possibility that reduced GAD67 activ-
ity may cause CP in the patients studied herein, in a
manner reminiscent of that seen in SPS, leads us to report
our findings at this stage. The success reported in treating
SPS with intravenous immunoglobulin [40,46], suggests
further evaluation of GABA agonists in the management
of this difficult clinical problem.
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